





THE FIGHT AGAINST ALZHEIMER'S DISEASE


Alzheimer's disease is the most common type of dementia accounting for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.

WHAT WE'RE UP AGAINST



Alzheimer's Disease International's WORLD ALZHEIMER REPORT 2015, the number of people living with Alzheimer's disease or other dementias will increase to nearly 74.7 million by 2030 and over 131.5 million by 2050.











seniors dies with

leading cause of death in US




COSTS OF CARING FOR PEOPLE WITH ALZHEIMER'S DISEASE

According to the ALZHEIMER'S ASSOCIATION, the annual societal costs for Alzheimer's disease globally is \$259 billion is 2017 and will rise to \$1.1 trillion by 2050.

IN 2016 AMERICANS PROVIDED

OF UNPAID CARE









No of clinical studies =



No of clinical sites =





DISEASE STUDY THAT IS AT THE CORNERSTONE OF THE NEW ALZHEIMER'S PREVENTION INITIATIVE AND COULD LEAD TO TREATMENTS DELAYING OR PREVENTING SYMPTOMS IN PEOPLE GENETICALLY PREDISPOSED TO THE DISEASE

PRA IS PARTICIPATING IN A GROUNDBREAKING ALZHEIMER'S

NEUROSCIENCE CLINICAL DEVELOPMENT STRATEGIES & EXPERTISE



Extensive experience facilitating patient advocacy groups and associations to optimize patient recruitment and motivate



and site selection.

Novel database analytics facilitate strategic country



Potential trial participants and their caregivers receive comprehensive education, communication and support

throughout the study.



Skilled project management and clinical operations staff with up to 30+ years experience.

investigators.